Dillon & Associates Inc. Acquires 1,276 Shares of Eli Lilly and Company (NYSE:LLY)

Key Points

• Dillon & Associates Inc. has increased its holdings in Eli Lilly by 102.4% in the first quarter, now owning a total of 2,522 shares valued at approximately $2.08 million.
• Eli Lilly reported a strong earnings performance with an EPS of $6.31, exceeding estimates and showing a 37.6% revenue growth compared to the previous year.
• The company announced a quarterly dividend of $1.50 per share, representing an annualized yield of 1.0% with a payout ratio of 48.82%.

Dillon & Associates Inc. grew its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 102.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,522 shares of the company's stock after buying an additional 1,276 shares during the period. Dillon & Associates Inc.'s holdings in Eli Lilly and Company were worth $2,083,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Capital Planning Advisors LLC boosted its stake in Eli Lilly and Company by 5.6% in the 1st quarter. Capital Planning Advisors LLC now owns 3,033 shares of the company's stock worth $2,505,000 after purchasing an additional 162 shares in the last quarter. PCG Asset Management LLC raised its position in Eli Lilly and Company by 47.4% in the 1st quarter. PCG Asset Management LLC now owns 429 shares of the company's stock worth $354,000 after buying an additional 138 shares during the last quarter. AIA Group Ltd raised its position in Eli Lilly and Company by 25.8% in the 1st quarter. AIA Group Ltd now owns 33,570 shares of the company's stock worth $27,726,000 after buying an additional 6,880 shares during the last quarter. Motley Fool Asset Management LLC increased its position in shares of Eli Lilly and Company by 16.5% during the 1st quarter. Motley Fool Asset Management LLC now owns 45,878 shares of the company's stock valued at $37,891,000 after purchasing an additional 6,503 shares during the last quarter. Finally, Ballast Inc. increased its position in shares of Eli Lilly and Company by 1.4% during the 1st quarter. Ballast Inc. now owns 4,306 shares of the company's stock valued at $3,556,000 after purchasing an additional 60 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $625.15 on Monday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $972.53. The company has a market cap of $591.68 billion, a PE ratio of 40.86, a P/E/G ratio of 0.87 and a beta of 0.44. The business has a 50-day simple moving average of $774.10 and a two-hundred day simple moving average of $799.34.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%. The firm had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the previous year, the company posted $3.92 earnings per share. The company's revenue was up 37.6% compared to the same quarter last year. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be given a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 1.0%. Eli Lilly and Company's payout ratio is 48.82%.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, Director Jamere Jackson acquired 200 shares of the business's stock in a transaction dated Friday, August 8th. The stock was acquired at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares of the company's stock, valued at $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.14% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. UBS Group reduced their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a report on Friday. Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. HSBC lowered shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their target price for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. Leerink Partnrs lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday. Finally, Guggenheim upped their price target on Eli Lilly and Company from $936.00 to $942.00 and gave the stock a "buy" rating in a research note on Friday, July 11th. One research analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $984.41.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.